Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Jiangsu Target Biomedical Research Institute Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner in 1 distinct art unit, indicating a specific focus for the company's current patent activities. In the Biotechnology & Pharmaceuticals sector, this level of concentration often points to a specialized technical filing that falls under a single administrative group.
The busiest examiner for this portfolio is HIBBERT, CATHERINE S, who is currently overseeing 1 busiest examiner pending action. Because there is 1 distinct examiner and 1 distinct art unit involved, the company's immediate prosecution success is tied to the review of HIBBERT, CATHERINE S. This centralization means that the outcome of the 1 pending office action will be the primary factor in the company's current patent strategy.
The presence of 1 distinct examiner allows the practitioner to develop a focused approach that addresses the specific concerns of HIBBERT, CATHERINE S. Since the 1 pending office action is situated within 1 distinct art unit, the procedural requirements are likely to be consistent and predictable. This streamlined arrangement reduces the administrative burden of managing multiple examiner perspectives for the 1 busiest examiner pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247684 | USE OF PHOSPHATIDYLSERINE IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY BOWEL DISEASE | HIBBERT, CATHERINE S | 7d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18247684 | USE OF PHOSPHATIDYLSERINE IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY BOWEL DISEASE | HIBBERT, CATHERINE S | 1658 | §103 | Non-Final OA | 7d | Pending | Apr 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Target Biomedical Research Institute Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine S Hibbert has the most, with 1 of Jiangsu Target Biomedical Research Institute Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
